Global Triptan Market Growth 2023-2029

Global Triptan Market Growth 2023-2029

Triptans are a family of tryptamine-based drugs used as abortive medication in the treatment of migraines and cluster headaches. This drug class was first introduced in the 1990s. While effective at treating individual headaches, they do not provide preventive treatment and are not considered a cure. 

LPI (LP Information)' newest research report, the “Triptan Industry Forecast” looks at past sales and reviews total world Triptan sales in 2022, providing a comprehensive analysis by region and market sector of projected Triptan sales for 2023 through 2029. With Triptan sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Triptan industry.

This Insight Report provides a comprehensive analysis of the global Triptan landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Triptan portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Triptan market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Triptan and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Triptan.

The global Triptan market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Triptan is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Triptan is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Triptan is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Triptan players cover GSK, Teva, Pfizer, Novartis, Sun Pharma, Grunenthal, Endo Pharmaceuticals, Merck and J & J, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Triptan market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Oral
Injectable

Segmentation by application
Hospital Pharmacies
Drug Stores

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GSK
Teva
Pfizer
Novartis
Sun Pharma
Grunenthal
Endo Pharmaceuticals
Merck
J & J

Key Questions Addressed in this Report

What is the 10-year outlook for the global Triptan market?

What factors are driving Triptan market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Triptan market opportunities vary by end market size?

How does Triptan break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.